Switzerland· 41217081

Holoxan

A ifosfamide product containing ifosfamidum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01AA06

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedHoloxanATCL01AA06REGISTER NO.41217081PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Ifosfamide is registered in 15 of 19 countries.

Countries holding a registration under ATC L01AA06 (ifosfamide), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Ifosfamide · ATC L01AA06

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ifosfamide costs, country by country.

Normalised to the WHO defined daily dose (0.7 g), so markets compare like for like.

  • Switzerland: $52.67 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ifosfamide · price per daily dose (0.7 g)

USD · FX 28 Sept 2026

  • CH Switzerland$52.67
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
ifosfamidum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01AA06
ATC class
Ifosfamide
Defined daily dose
0.7 g, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680412170817
    Durchstf 1 Stk
    CHF 43.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

514 interactions on record for ifosfamide.

Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ifosfamide · interactions on record

514 records

  • 41 severe
  • 385 moderate
  • 16 minor
  • 72 info

Most severe, free to view

  • Nalidixic acidJ01MB02severe
  • CidofovirJ05AB12severe
  • ThiotepaL01AC01severe
  • CladribineL01BB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ifosfamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ifosfamide products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Holoxan
  • Belgium · Holoxan
  • Bulgaria · Холоксан
  • Czechia · Holoxan
  • Germany · Holoxan, Ifo-Cell
  • Denmark · Holoxan
  • Estonia · Holoxan
  • Spain · Tronoxal
  • Finland · Holoxan
  • France · Holoxan, Ifosfamide Eg
  • United Kingdom (Northern Ireland) · Ifosfamide Baxter Healthcare
  • Greece · Holoxan
  • Croatia · Holoxan
  • Hungary · Holoxan
  • Ireland · Mitoxana
  • Iceland · Holoxan
  • Italy · Holoxan
  • Lithuania · Holoxan
  • Luxembourg · Holoxan
  • Latvia · Holoxan
  • Malta · Mitoxana
  • Netherlands · Holoxan
  • Norway · Holoxan
  • Poland · Holoxan
  • Portugal · Holoxan
  • Romania · Holoxan
  • Sweden · Holoxan
  • Slovenia · Holoxan
  • Slovakia · Holoxan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/beb5e0a8-2112-4997-a5ea-efadb97dfc37
GET /v1/drugs/beb5e0a8-2112-4997-a5ea-efadb97dfc37?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "ifosfamidum 500 mg",
  "valid_from": "1982-03-15",
  "limitations": null,
  "galenic_form": "Trockensub 500 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "1982-03-15",
  "self_retention_pct": 10
}

See everything about ifosfamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.